Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ABAT | P80404 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098290 | 0.87 | AGXT (0.38) | CA2 | |
| SCHEMBL10098045 | 0.84 | IDO1 (0.35) | IDO1ESR2ESR1MEN1KMT2A | |
| SCHEMBL10098121 | 0.73 | — | — | |
| SCHEMBL10098056 | 0.72 | IDO1 (0.33) | IDO1ESR2CA2 | |
| SCHEMBL10096874 | 0.71 | AGXT (0.38) | CA2 | |
| SCHEMBL10096903 | 0.69 | AGXT (0.36) | CA2 | |
| SCHEMBL10098097 | 0.66 | IDO1 (0.36) | IDO1ESR2ESR1MEN1KMT2A | |
| SCHEMBL10098323 | 0.65 | IDO1 (0.35) | IDO1ESR2ESR1MEN1KMT2A | |
| SCHEMBL1846696 | 0.65 | IDO1 (0.42) | IDO1ESR2ESR1MEN1KMT2A | |
| SCHEMBL1837160 | 0.63 | ESR1 (0.42) | IDO1ESR2ESR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124196-B2 | Fluorobicyclo[2.2.2]octane compound, method of producing the same, and applications thereof | FUJIFILM CORPORATION (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20100231844-A1 | FLUOROBICYCLO[2.2.2]OCTANE COMPOUND, METHOD OF PRODUCING THE SAME, AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100231844-A1 | FLUOROBICYCLO[2.2.2]OCTANE COMPOUND, METHOD OF PRODUCING THE SAME, AND APPLICATIONS THEREOF | AFF2, FPR2, SLCO1A2 | IDO1 1484/4885ESR2 556/4885ESR1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.